Mr. John E. Lucas,
President and CEO,
TransGenex Nanobiotech Inc.
BIO: Lucas most recently served as Chairman and Chief Executive Officer of EpiCept Corp. and
GmbH, Englewood Cliffs, New Jersey, and Munich, Germany, a company developing proprietary
Rx topical pain control products. For seven years until May, 2006, Mr. Lucas was a director of
Sequenom, Inc. (DNA analysis systems) where he served as Chairman of the Audit Committee
and member of the Compensation and Nominating committees. He also served as Special
Consultant organizing its successful $147 million initial public offering February 1, 2000.
Mr. Lucas began his management career in 1964 when he was recruited to serve as CEO of
Oxford Laboratories, San Mateo, California, a small company which produced clinical laboratory
devices and related supplies. Within a few years, following introduction of the first hand held
micropipette, the company began to grow rapidly and completed an initial public offering through
Hambrecht & Quist in 1970. G.D. Searle & Co. (now Monsanto) acquired the company in 1974.
Mr. Lucas left Oxford to found Chemetrics Corporation in Burlingame, California. Under his
leadership, Chemetrics developed and produced the first microprocessor-controlled clinical
chemistry analyzer, preceding major manufacturers by more than two years. Millipore
Corporation, Bedford, Massachusetts acquired the company in November 1979.
He assisted the CEO of Millipore in seeking investment and acquisition opportunities until early
1981 when he co-founded XOMA Corporation, one of the first biotechnology companies. He led
a series of private placements through major investment banks and, in 1986, he organized an
initial public offering through Alex. Brown and Dillon Read. He hired a successor CEO and
remained on the board for another year through a similar follow-on public offering.
In June 1986, he took over as CEO of a venture capital financed company, MAST
Immunosystems, Inc., Mountain View, California. MAST produced novel in vitro allergy testing
systems but was near bankruptcy due to poor management. The company was operating
profitably within six months and, in 1992,was acquired by its Japanese distributor, Hitachi
In 1992, he became CEO of Oxigene, Inc., in New York and Lund, Sweden. Oxigene is working
on a range of cancer drugs. The company had an initial public offering in 1993. In 1994, all
management and research and development operations were moved to Sweden.
With a Harvard Business School classmate, he co-founded International Scientific Advisors in
San Francisco in 1994 which worked with a client companies in Bermuda and China setting up an
operation in Beijing to manufacture and distribute China’s first practical home blood glucose
testing system. In 1995, Mr. Lucas sold his interest in the company and moved to New York. and
in June, 2006, he moved to Sarasota, Florida
Mr. Lucas grew up in Illinois where he was a graduate of Western Military Academy
and Northwestern University. Following graduation, he served three years as a line officer in the
United States Navy after which, he attended the Harvard Business School and received an MBA